TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to stop rare heart disease in its tracks
Disease control OngoingThis phase 2b trial tests whether adding ALXN2220 to eplontersen works better than eplontersen alone for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 326 participants will receive either the combinati…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for rare heart disease: experimental drug tested for long-term safety
Disease control OngoingThis study tests the long-term safety of an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy, a rare heart disease that can lead to heart failure. All 80 participants have already completed an earlier study and will receive the drug every …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC